Tech Company Financing Transactions
Sequel Pharmaceuticals Funding Round
Domain Associates, Forward Ventures and InterWest Partners participated in a $20 million Series A funding round for Sequel Pharmaceuticals. This venture round closed on 9/27/2007.
Transaction Overview
Company Name
Announced On
9/27/2007
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series A
Investors
Proceeds Purpose
Randall E. Woods, president and chief executive officer at Sequel Pharmaceuticals said, "The funding we have received will enable us to initiate our Phase 2 clinical program for K201 for atrial fibrillation while we simultaneously pursue novel drug candidates to build our pipeline in cardiovascular disease."
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
12790 El Camino Real 300
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Website
Email Address
Overview
Sequel Pharmaceuticals is a privately held product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing novel clinical-stage drug candidates.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Randall Woods
Browse more venture capital transactions:
Prev: 9/26/2007: Miasole venture capital transaction
Next: 9/27/2007: Mashery venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. VC investment data records reported here are derived from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs